A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off" (TOZ-PD)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms TOZ-PD
  • Sponsors Acorda Therapeutics; Biotie Therapies Corp.
  • Most Recent Events

    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
    • 09 Feb 2018 This trial has been Discontinued in Austria according to European Clinical Trials Database record.
    • 20 Jan 2018 This trial has been completed in Czech Republic (end date: 2018-01-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top